Hospital
Jordan Valley Medical Center LP
Jordan Valley Medical Center LP was paid $9.07M by Medicaid between Jan 2018 and Feb 2023, across 109 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 79% of everything it billed.
33Billing provider infoJORDAN VALLEY MEDICAL CENTER LP
WEST JORDAN, UT 84088
WEST JORDAN, UT 84088
33aNPI1144490160assigned 03/05/2008
33bProvider typeRehabilitation Hospital Unit
28Total paid$9.07M
24GClaims110,052
24DCodes billed109
24AFirst – last monthJan 2018 – Feb 2023
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,356 | $1.56M | |
| 2019 | 15,993 | $1.36M | |
| 2020 | 20,477 | $1.93M | |
| 2021 | 31,052 | $2.44M | |
| 2022 | 21,618 | $1.72M | |
| 2023 | 556 | $55K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 79% | 26,326 | 8,520 | $7.21M |
| 36415 | Collection of venous blood by venipuncture | 12% | 8,383 | 6,670 | $1.06M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.5% | 762 | 719 | $138K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.4% | 3,809 | 3,589 | $128K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | <1% | 3,926 | 3,581 | $52K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 939 | 868 | $51K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,606 | 3,069 | $31K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 296 | 282 | $29K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 3,413 | 2,984 | $27K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 427 | 395 | $25K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,202 | 1,107 | $22K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 654 | 630 | $21K |
97 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,906 | $21K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 242 | $20K |
| 81001 | <1% | 2,396 | $18K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 301 | $17K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 820 | $15K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 104 | $14K |
| 82962 | <1% | 253 | $14K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 280 | $14K |
| 81003 | <1% | 1,434 | $13K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 315 | $12K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 308 | $9K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,680 | $8K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,616 | $7K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,094 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 726 | $6K |
| 80053 | Comprehensive metabolic panel | <1% | 5,483 | $6K |
| 87088 | <1% | 418 | $5K | |
| 84703 | <1% | 1,676 | $5K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 281 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,713 | $4K |
| 59025 | Fetal non-stress test | <1% | 507 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 170 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 277 | $4K |
| J3490 | Unclassified drugs | <1% | 29 | $4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 37 | $4K |
| 83690 | <1% | 1,747 | $3K | |
| 99001 | <1% | 90 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 50 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,649 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 66 | $3K |
| 86710 | <1% | 54 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,758 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,837 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 82 | $2K |
| 87400 | <1% | 69 | $2K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 91 | $2K |
| 80050 | General health panel | <1% | 624 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 35 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 897 | $1K |
| 80143 | <1% | 154 | $999.10 | |
| 87081 | <1% | 18 | $924.97 | |
| 31720 | <1% | 19 | $917.94 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 840 | $842.16 |
| 87077 | <1% | 44 | $802.28 | |
| 87631 | <1% | 13 | $662.66 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 86 | $620.20 |
| 81025 | <1% | 281 | $579.28 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 520 | $546.08 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 115 | $428.80 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 13 | $336.51 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,505 | $300.00 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,847 | $299.59 |
| 99152 | <1% | 42 | $274.11 | |
| A9270 | Non-covered item or service | <1% | 1,688 | $248.47 |
| 94760 | <1% | 567 | $181.89 | |
| 93971 | <1% | 13 | $115.64 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 28 | $68.68 |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 26 | $65.64 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 221 | $40.00 |
| 82077 | 0% | 273 | $0.00 | |
| 96376 | 0% | 613 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 781 | $0.00 |
| 83605 | 0% | 159 | $0.00 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 338 | $0.00 |
| 85379 | 0% | 109 | $0.00 | |
| 84484 | 0% | 1,082 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 111 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 528 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 367 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 58 | $0.00 |
| 80320 | 0% | 33 | $0.00 | |
| 86140 | 0% | 14 | $0.00 | |
| 88342 | 0% | 103 | $0.00 | |
| 83880 | 0% | 98 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 147 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 97 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 163 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 33 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 83 | $0.00 |
| 85730 | 0% | 25 | $0.00 | |
| 83735 | 0% | 13 | $0.00 | |
| 85652 | 0% | 14 | $0.00 | |
| 82607 | 0% | 32 | $0.00 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 19 | $0.00 |
| 80329 | 0% | 25 | $0.00 | |
| 87503 | 0% | 12 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 434 | $0.00 |
| 80179 | 0% | 148 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 634 | $0.00 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 34 | $0.00 |
| 80061 | Lipid panel | 0% | 119 | $0.00 |
| 85610 | 0% | 258 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 34 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 25 | $0.00 |
| 87186 | 0% | 63 | $0.00 | |
| 84439 | 0% | 44 | $0.00 | |
| 87420 | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, STEVEN (HOSPITAL CEO)
Parent organizationJORDAN VALLEY MEDICAL CENTER LP
| Provider | Location | Paid |
|---|---|---|
| Jordan Valley Medical Center LP | West Valley City, UT | $15.57M |
| Jordan Valley Medical Center LP | West Jordan, UT | $7.27M |
| Jordan Valley Medical Center LP | Lehi, UT | $5.61M |
| Americare Assisted Living, INC | Deltona, FL | $1.41M |
| Jordan Valley Medical Center LP | West Valley City, UT | $65K |
| Crowders Neighborhood Drug Store INC | Bedford, IN | $27K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.